

WELCOME TO THE NCCN 2021 VIRTUAL ONCOLOGY FELLOWS PROGRAM

NCCN would like to thank the outstanding faculty who are presenting and all of you for attending this educational event. We hope you find the information presented useful to your practice, and we encourage you to attend future NCCN educational initiatives.

Agenda	PAGE	2
ACCREDITATION INFORMATION		3 - 5
SUPPORTING ORGANIZATIONS	PAGE	4
CLAIMING CREDIT	PAGE	5
DISCLOSURE INFORMATION	PAGES	6 - 8
FACULTY BIOGRAPHIES	PAGES	9 – 14

PDF handouts of the presentations are available at <u>education.nccn.org/NCCN2021FP-handouts</u>.



Agenda

12:30 – 12:40 рм	Opening Remarks Wui-Jin Koh, MD Senior Vice President/Chief Medical Officer <i>National Comprehensive Cancer Network</i>
12:40 — 1:10 рм	Telemedicine and Cancer Care: Lessons for the Future Sandra S. Hatch, MD <i>The University of Texas MD Anderson Cancer Center</i> <i>The University of Texas Medical Branch at Galveston</i>
1:15 – 2:00 рм	Optimal Management of Venous Thromboembolism in Patients with Cancer Michael B. Streiff, MD <i>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</i>
2:00 – 2:15 рм	Break
2:15 – 2:45 рм	Survivorship: From Adolescents and Young Adults to Older Adults Christine E. Hill-Kayser, MD Abramson Cancer Center at the University of Pennsylvania
2:50 — 3:50 рм	Multidisciplinary Treatment of Early-Stage Non-Small Cell Lung Cancer Thomas J. Dilling, MD, MS Moffitt Cancer Center
	Michael Lanuti, MD Massachusetts General Hospital Cancer Center
	Gregory A. Otterson, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
3:50 — 4:05 рм	Break
4:05 – 5:05 pm	Multidisciplinary Treatment of Prostate Cancer Anthony V. D'Amico, MD, PhD Dana-Farber/Brigham and Women's Cancer Center
	Tanya Dorff, MD <i>City of Hope National Medical Center</i>
	Edward Schaeffer, MD, PhD Robert H. Lurie Comprehensive Cancer Center of Northwestern University
5:10 — 5:55 рм	The Importance of Mentorship Stéphanie Gaillard, MD, PhD <i>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</i>
	Elaine Walsh, MB BCh, PhD <i>Memorial Sloan Kettering Cancer Center</i>
5:55 — 6:00 рм	Closing Remarks



Accreditation Information

Program Overview

The purpose of the NCCN 2021 Virtual Oncology Fellows Program: New Horizons in Quality Cancer Care[™] is to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) and other evidence-based treatment principles in the management of significant cancer types and supportive care and professional development issues.

The goal of this activity is to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.

Intended Audience

This educational program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

Learning Objectives

Following this program, participants should be able to:

Overall Program Objectives

- Evaluate advances in the management of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
- Review issues related to telemedicine and cancer care: lessons for the future; optimal management of VTE in cancer patients; survivorship: from AYA to older adults; multidisciplinary management of early-stage lung cancer; and, multidisciplinary treatment of prostate cancer; and the importance of mentorship.

Telemedicine and Cancer Care: Lessons for the Future

- Review the benefits of telemedicine for cancer care.
- Identify the unique challenges and limitations that can arise with telemedicine.
- Determine which patient encounters are appropriate for telemedicine.

Optimal Management of Venous Thromboembolism in Patients with Cancer

- Describe clinical situations where therapeutic anticoagulation would be an appropriate option for treatment of cancer-associated venous thromboembolism (VTE).
- List factors to consider (including contraindications) when selecting among the recommended options for therapeutic VTE anticoagulation in patients with cancer.
- Describe consideration for management of patients with cancer-associate VTE in the event of therapeutic anticoagulation failure.

Survivorship: From Adolescents and Young Adults to Older Adults

- List common physical, psychological, and psychosocial late and long-term effects associated with cancer and its treatment.
- Discuss special considerations for survivorship care in AYA and older adult populations.
- Develop strategies for screening and management of late and long-term effects and for encouraging wellness in cancer survivors of all ages.



Accreditation Information

Learning Objectives (continued)

Multidisciplinary Treatment of Early-Stage Non-Small Cell Lung Cancer

- Discuss the need for multidisciplinary evaluation before treatment for patients with early-stage non-small cell lung cancer (NSCLC).
- Describe multidisciplinary treatment for patients with medically operable early-stage NSCLC.
- Describe multidisciplinary treatment for patients with medically inoperable early-stage NSCLC.

Multidisciplinary Treatment of Prostate Cancer

- Provide an overview of the treatments used to treat patients with prostate cancer.
- Discuss the roles that genetics and diagnostic radiology professionals play in the optimal management of prostate cancer.
- Understand management strategies for supportive care issues in patients with prostate cancer.

The Importance of Mentorship

- Explain the benefits of the mentor-mentee relationship and learn how to get the most out of this relationship.
- Recognize the qualities and attributes of an appropriate mentor and how to identify the right match.
- Describe the difference between a mentor, a sponsor, and a coach.

Supporting Organizations

This activity is supported by educational grants from:

- AstraZeneca
- Genentech, a member of the Roche Group
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
- Pfizer

This activity is supported by an independent medical education grant from Bristol Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Supporter list updated March 15, 2021.

Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

NCCN designates this live activity for a maximum of 4.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Accreditation Information

How to Claim CE Credit

Before or during the activity, please ensure that you have an NCCN account and will receive the correct type of credit.

- 1. Log in at <u>www.NCCN.org</u>
 - If you do not have an NCCN account, click "Sign up here" to create one for free.
- 2. Click "Profile" in the left side menu.
- 3. Verify that your **User Type** matches the type of credit you will claim:
 - Physician/Surgeon/Oncologist = AMA PRA Category 1 Credits™
 - All other user types = certificate of participation
- 4. Scroll down and click "Save" if you make any changes.

Immediately after the activity, follow the instructions below to complete the CE requirements online through NCCN's Continuing Education Portal.

You will need to log in with the same email address used for program registration:

- 1. Log in at education.nccn.org/fellows2021
- 2. Click the Take Course button.
- 3. Follow the prompts.

Requirements for Receiving CE Credit

Within 30 days of the activity, you must:

- Attend the activity.
- Complete the immediate post-test.
- Complete the evaluation.
- Claim your credits.

You will be able to view/print your certificate online once all requirements have been met.

If you have any questions, please email <u>education@nccn.org</u>.



Disclosure Information

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.

Definitions

NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.

NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.



Disclosure Information

Faculty Disclosures

The faculty listed below discloses **no relevant** financial relationships:

Anthony V. D'Amico, MD, PhD Stéphanie Gaillard, MD, PhD Sandra S. Hatch, MD Christine E. Hill-Kayser, MD Elaine Walsh, MB BCh, PhD

The faculty listed below discloses the following **relevant** financial relationships:

Thomas J. Dilling, MD, MS AstraZeneca Pharmaceuticals LP: Consulting Fee; Honoraria

Tanya Dorff, MD

AbbVie, Inc.: Consulting Fee Bayer HealthCare: Consulting Fee Exelixis Inc.: Consulting Fee Janssen Pharmaceutica Products, LP: Consulting Fee

Stéphanie Gaillard, MD, PhD AstraZeneca Pharmaceuticals LP: Consulting Fee Elevar Therapeutics: Consulting Fee

Michael Lanuti, MD AstraZeneca Pharmaceuticals LP: Consulting Fee

Gregory A. Otterson, MD

AbbVie, Inc.: Grant/Research Support Astellas Pharma US, Inc.: Grant/Research Support AstraZeneca Pharmaceuticals LP: Grant/Research Support; Consulting Fee Bristol-Myers Squibb Company: Grant/Research Support; Consulting Fee Genentech, Inc.: Grant/Research Support Gilead Sciences, Inc.: Consulting Fee Merck & Co., Inc.: Grant/Research Support Novocure: Consulting Fee Pfizer Inc.: Grant/Research Support Revolution Medicine: Grant/Research Support

Edward Schaeffer, MD, PhD Janssen Scientific Affairs, LLC: Scientific Advisor Pfizer Inc.: Scientific Advisor

Michael B. Streiff, MD

Bayer HealthCare: Honoraria Bristol-Myers Squibb Company: Scientific Advisor; Consulting Fee Dispersol Technologies: Consulting Fee Janssen Pharmaceutica Products, LP: Scientific Advisor; Consulting Fee Novo Nordisk A/S: Grant/Research Support Pfizer Inc.: Consulting Fee; Honoraria sanofi-aventis U.S.: Grant/Research Support

This list includes disclosures of relevant financial relationships submitted to NCCN as of March 12, 2021.



Disclosure Information

NCCN Staff Disclosures

The NCCN Leadership listed below discloses **no relevant** financial relationships:

Wui-Jin Koh, MD

The NCCN Activity Planning staff listed below discloses **no relevant** financial relationships:

Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses **no relevant** financial relationships:

Deborah A. Freedman-Cass, PhD; Anita M. Engh, PhD; Liz Hollinger, RN, BSN; Miranda Hughes, PhD; Nicole R. McMillian, MS, CHES; Dorothy A. Shead, MS



Anthony V. D'Amico, MD, PhD, is the Eleanor Theresa Walters Distinguished Chair and Chief of Genitourinary Radiation Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital. He also serves as Chair of the Residency Executive Committee in the Harvard Radiation Oncology Program, as well as Advisory Dean and Chair of Career Advising and Mentorship at Harvard Medical School.

Dr. D'Amico holds two undergraduate and three graduate degrees from the Massachusetts Institute of Technology, including: a bachelor's of science in physics; a bachelor's of science in nuclear engineering; a master's of science in nuclear engineering; and a doctorate of philosophy in radiation physics. He received his medical degree from the University of Pennsylvania School of Medicine and completed his radiation oncology residency at the Hospital of the University of Pennsylvania, where he served as Chief Resident in his final year.

Dr. D'Amico is an internationally known expert in the treatment of prostate cancer. Among his accomplishments, he has defined combined modality staging, which is used to select patients with localized prostate cancer for specific surgical or radiotherapeutic treatment options. He is the Principal Investigator for several ongoing federally-funded clinical trial grants. His current research focuses on image-guided therapy for early-stage prostate cancer, drug development for advanced-stage prostate cancer, and defining future management strategies for men with prostate cancer. He also is developing and testing molecular imaging and identifying genomic risk classification profiles. This work holds promise for significantly improving how prostate cancer is detected and treated, with potential to develop more personalized therapies for prostate cancer care.

In addition to his clinical work, Dr. D'Amico's teaching contributions include his service as Head of the Executive Committee of the Harvard Combined Residency in Radiation Oncology and Master of the Oliver Wendell Holmes Society at Harvard Medical School. Dr. D'Amico also has more than 350 peer-reviewed original publications and editorials. In December 2016, his editorial on a landmark prostate cancer study in *New England Journal of Medicine* was cited in *The New Yorker* as one of the most notable medical findings that year. Additionally, he is an editorial board member for 6 scientific journals, an expert reviewer for 14 journals including *New England Journal of Journal of Medicine* and *Journal of the American Medical Association*, and an editor of 4 textbooks on the management of prostate cancer.

Over the course of his career, Dr. D'Amico has amassed a plethora of accolades from prominent institutions and professional organizations. From Harvard Medical School, he is a past-recipient of the *Arnold P. Gold Award for Humanism in Medicine*, a 2-time recipient of the *Career Advising and Mentoring Faculty Teaching Award*, and a 3-time recipient of the *Faculty Mentoring and Teaching Award*. In 2015, he received the *Morton M. Kligerman Award* from the Hospital of the University of Pennsylvania, a distinction awarded to a physician in the Department of Radiation Oncology whose dedication to research improves the lives of patients with cancer. Dr. D'Amico also has been recognized with the *Best Doctor in America* award annually since 2009. Most recently, he was awarded the *Grant V Rodkey, MD Award for Outstanding Contributions to Medical Education* by the Massachusetts Medical Society.

Dr. D'Amico is a member of the NCCN Prostate Cancer Panel.



Thomas J. Dilling, MD, MS, is Chief of the Thoracic Radiotherapy Program at Moffitt Cancer Institute. Dr. Dilling also holds a faculty appointment as Professor in the Department of Oncologic Sciences at the University of South Florida.

Dr. Dilling received his medical degree from University of Pennsylvania, where he subsequently completed his internal medicine residency and fellowship in radiation oncology. He also has a master's degree in information technology.

Dr. Dilling has authored or co-authored numerous journal articles and book chapters. He is an advisory committee member to the American Board of Radiology and serves as Vice-Chair of the Annual Meeting Education Committee for the American Society for Radiation Oncology (ASTRO).

Dr. Dilling is a member of the NCCN Guidelines Panel for Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas and serves as the panel's radiation reviewer. Dr. Dilling also has served on several committees in an advisory capacity for the NCCN Oncology Research Program.

Tanya Dorff, MD, is Head of the Genitourinary Cancers Program at City of Hope National Medical Center, where she also serves as Associate Clinical Professor in the Department of Medical Oncology & Therapeutics Research.


Dr. Dorff earned her medical degree at the UCLA School of Medicine, where she was inducted into the prestigious *Alpha Omega Alpha* Honors Society. She subsequently completed her internal medicine residency at The Mount Sinai Hospital in New York and her subspecialty training in hematology and medical oncology at LAC + USC Medical Center in California.

Dr. Dorff is an internationally recognized leader in prostate cancer and also is renowned for her expertise in other genitourinary tumor types, including kidney, bladder, and penile cancer. Her clinical work is focused on the design and conduct of trials related to PSA-recurrent prostate cancer, referring to the setting in which local therapies fail and blood-based markers continue to rise. For patients with more advanced prostate cancer, she has studied the role of fasting as it pertains to chemotherapy tolerability, with very compelling early results.

In her current role at City of Hope, Dr. Dorff is responsible for one of the largest clinical trial portfolios in genitourinary cancers and sees patients with prostate, bladder, testicular, and penile cancer. She also leads City of Hope's joint effort with the Prostate Cancer Foundation to develop novel immune-based strategies for prostate cancer and currently is involved in a collaboration with the Translational Genomics Research Institute to develop first-in-human agents to combat prostate cancer through other novel mechanisms.

Dr. Dorff has amassed more than 70 publications in prominent scientific journals, including *Cancer*, *Lancet Oncology*, and *Journal of Clinical Oncology*. She also serves on the National Cancer Institute Prostate Cancer Task Force.

Dr. Dorff is a member of the NCCN Prostate Cancer Panel.



Stéphanie Gaillard, MD, PhD, is Director of Gynecologic Cancer Trials and Assistant Professor of Oncology and Gynecology/Obstetrics at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Prior to joining Johns Hopkins, she was a faculty member at Duke University Medical Center.

Dr. Gaillard earned her medical degree and doctorate of philosophy in cancer biology from Duke University. She then completed her residency training in internal medicine and fellowship training in medical oncology at The Johns Hopkins School of Medicine.

Dr. Gaillard specializes in the treatment of gynecologic malignancies, including ovarian, endometrial, and cervical cancers. Her work focuses on developing clinical trials that aim to improve outcomes using promising new biologic, targeted, and immune therapies in addition to standard treatment regimens. Her translational research program focuses on understanding mechanisms of resistance to therapy and the immune environment associated with gynecologic cancers.

Dr. Gaillard has been honored with several awards in her career, including the *Liz Tilberis Early Career Award* from the Ovarian Cancer Research Fund and a *Young Investigator Award* from the Conquer Cancer Foundation. She was a scholar for the NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) and is a recipient of the Gynecologic Oncology Group (GOG) Foundation *Scholar Investigator Award*.

Dr. Gaillard serves as Co-Chair of the NRG Oncology Phase I subcommittee. She is the primary author or co-author of numerous publications and book chapters and has presented her research both domestically and abroad.

Sandra S. Hatch, MD, is a tenured Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center and Medical Director of The University of Texas Medical Branch (UTMB) - Galveston.

In addition to her current roles, Dr. Hatch is the Irma Labardini Mendoza and Jesse Jesus Mendoza Distinguished Chair in Breast and Gynecologic Malignancies, established for Dr. Hatch by a grateful patient. She also holds the Ruth Levy Kempner Professorship in Breast Cancer, awarded for her leadership in breast cancer patient-centered care. Dr. Hatch also holds several other positions at UTMB, including Adjunct Professor and Chair ad Interim, the John Sealy Distinguished Centennial Chair in Radiation Therapy, and Faculty Scholar in the John P. McGovern Academy of Oslerian Medicine.

Dr. Hatch received her medical training at the University of Texas Health Science Center. She subsequently completed a transitional internship at the Central Texas Medical Foundation and a radiation oncology residency at Baylor College of Medicine.

Dr. Hatch's practice focuses on gynecologic and breast malignancies. She is the Principal Investigator for numerous collaborative trials in these areas. She also holds two endowments for ongoing research activities studying targeted therapies for glioblastoma and pathways in breast cancer subtypes. Additionally, Dr. Hatch is an established educator and serves in a mentorship capacity for pre-admission students, medical students, residents, and fellows at UTMB Medical School.

Dr. Hatch holds memberships with a number of scientific societies, including the American Society for Therapeutic Radiology & Oncology, the Texas Radiological Society, the American College of Radiology, and the NRG Radiation Therapy Oncology Group and Gynecology Oncology Group. She also serves as a scientific advisor for both national and local organizations, including the Susan G. Komen Medical Advisory Council, the Breast Collaborative Group of Texas, the Texas Breast and Cervical Cancer Control Clinical Workgroup, the Susan G. Komen Houston Medical Advisory Council, and the Partners in Pink Breast Cancer Coalition Galveston County Advisory Committee. She is an editorial board member for *Journal of Clinical Radiation Oncology.*



Christine E. Hill-Kayser, MD, is Chief of the Pediatric Radiation Oncology Service at the Children's Hospital of Philadelphia and Associate Professor of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania. She also is a member of the Roberts Proton Therapy Center at the Abramson Cancer Center at the University of Pennsylvania.

Dr. Hill-Kayser earned her medical degree from the University of Pennsylvania School of Medicine. She completed her internship at the Albert Einstein Medical Center and a radiation oncology residency at the University of Pennsylvania, during which time she served as Assistant Chief Resident and Chief Resident. She is board-certified in radiation oncology.

Dr. Hill-Kayser's areas of expertise include external beam radiation therapy, proton therapy, and pediatric cancer, with a particular focus on Wilms' Tumor and other pediatric abdominal tumors. She has published extensively on these topics across a variety of cancer types. She also has a special interest in survivorship and adolescent and young adult oncology.

Dr. Hill-Kayser is a member of several professional organizations, including the American Association for Cancer Research, the American Society of Clinical Oncology, American Society of Radiation Oncology, the Children's Oncology Group, the Pediatric Proton Consortium Registry, and the Pediatric Radiation Oncology Society. She also serves on the Pediatric Subcommittee of the Proton Cooperative Group. Additionally, Dr. Hill-Kayser is Editor-in-Chief of *OncoLink* and Assistant Senior Editor at the International Journal of Radiation Oncology Biology & Physics; she serves as a reviewer for a number of peer-reviewed publications, including *Annals of Oncology, Journal of Pediatric Hematology & Oncology, Cancer,* and *Journal of Clinical Oncology.*

Dr. Hill-Kayser is a member of the NCCN Survivorship Panel.

Michael Lanuti, MD, is Director of Thoracic Oncology in the Division of Thoracic Surgery and the Friedman-Lambert Scholar in Academic Thoracic Surgery at Massachusetts General Hospital. He also holds a faculty appointment as Associate Professor of Surgery at Harvard Medical School.

Dr. Lanuti earned his medical degree from the University of Pennsylvania School of Medicine. He completed his surgical internship and residency at the Hospital of the University of Pennsylvania, followed by a research fellowship in a thoracic oncology laboratory focusing on novel treatments for lung cancer. He continued with subspecialty training and completed a cardiothoracic fellowship at Massachusetts General Hospital.

Dr. Lanuti has been involved in translational research for close to 25 years. His clinical interests include minimally invasive surgery for lung cancer, complex airway tumors, multimodality treatment of esophageal cancer, mediastinal tumors, navigation bronchoscopy, percutaneous and bronchoscope thermal ablation of lung tumors, and surgery for hyperhidrosis. He is the Principal Investigator or co-Principal Investigator for several ongoing NIH-funded clinical trials examining PET-imaging of pulmonary fibrosis.

Dr. Lanuti holds professional memberships with a number of prominent organizations and serves on the editorial board for several peer-reviewed publications, including *Surgery, Journal of Thoracic and Cardiovascular Surgery,* and *Annals of Thoracic Surgery.* His committee involvement includes the Society of Thoracic Surgeons Workforce on Evidence Based Surgery, the Lung Cancer Mutation Consortium Executive Committee, the Thoracic Surgery Oncology Group, and the American College of Chest Physicians Non-Small Cell Lung Cancer Guideline Panel.

Dr. Lanuti also serves as on the NCCN Guidelines Panel for Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas.



Gregory A. Otterson, MD, is Professor of Internal Medicine, Attending Physician in Solid Tumor Oncology, and Co-Director of the Thoracic Oncology Program at Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University.

Dr. Otterson received his medical degree from Georgetown University School of Medicine in Washington, District of Columbia. His postgraduate training included an internship and residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, Illinois and fellowship in medical oncology in the Clinical Oncology Program at the National Cancer Institute in Bethesda, Maryland.

Dr. Otterson holds memberships with a number of professional organizations, including: the Alliance for Clinical Trials in Oncology; the International Association for the Study of Lung Cancer; the American Association for Cancer Research; the American Society of Clinical Oncology; and the American College of Physicians.

Dr. Otterson has contributed to more than 100 publications, including journals, manuscripts, book chapters, book reviews, and abstracts and has lectured extensively on oncology.

Dr. Otterson is a member of the NCCN Non-Small Cell Lung Cancer Panel and the review committee for the NCCN Foundation Young Investigator Awards. He also has served on several committees in an advisory capacity for the NCCN Oncology Research Program.

Edward Schaeffer, MD, PhD, is Chair of the Department of Urology and Edmund Andrews Professor of Urology at Feinberg School of Medicine. He also serves as Program Director of the Genitourinary Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Dr. Schaeffer earned his medical degree at the University of Chicago. He subsequently completed a general surgery internship and urology residency at The Johns Hopkins University School of Medicine.

A clinically active urologist, Dr. Schaeffer specializes in prostate cancer. His globally recognized research focuses on at-risk populations, diagnosis, treatment outcomes, and the molecular biology of lethal prostate cancer.

Dr. Schaeffer is a member of the National Cancer Institute Genitourinary Cancers Steering Committee and a board member for the Society of Urologic Oncology Clinical Trials Consortium. He also sits on the editorial board for *Journal of Urology* and is an ad-hoc reviewer for numerous academic journals. He is a past-recipient of the American Urological Association/Astellas *Rising Star in Urology Award* and the American Society for Clinical Oncology *Clinical Cancer Advance of the Year Award*.

Dr. Schaeffer is Chair of the NCCN Prostate Cancer Panel and an editorial board member for JNCCN—Journal of the National Comprehensive Cancer Network.



Michael B. Streiff, MD, is Professor of Medicine and Pathology at The Johns Hopkins University School of Medicine, The Johns Hopkins Hospital, and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He also serves as Medical Director of the Johns Hopkins Anticoagulation Management Service and Outpatient Clinics, as well as Staff Physician at Johns Hopkins Comprehensive Hemophilia Treatment Center.

Dr. Streiff received his medical degree from The Johns Hopkins University School of Medicine. He completed an internship and residency in internal medicine at the University of Florida and a fellowship in hematology and oncology at The Johns Hopkins University.

Dr. Streiff's clinical and research interests focus on the prevention and treatment of venous thromboembolism and the management of anticoagulation, hemophilia, and other coagulation disorders. He has published more than 150 articles and book chapters in scientific journals such as *Journal of the American Medical Association*, *Journal of Clinical Oncology, Blood, British Medical Journal, The American Journal of Medicine*, and *Cancer.* Additionally, he has served on international consensus panels to develop standardized guidelines for the use of vena caval filters in the management of venous thromboembolism.

Dr. Streiff is Chair of the NCCN Cancer-Associated Venous Thromboembolic Disease Panel and a member of the editorial board for *JNCCN—Journal of the National Comprehensive Cancer Network*.

Elaine Walsh, MB BCh, PhD, is a medical oncologist and Assistant Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center.

Dr. Walsh earned her medical degree from the National University of Ireland Galway and received her board certification in internal medicine and medical oncology from the Royal College of Physicians of Ireland. She subsequently pursued a doctorate of philosophy at the National University of Ireland Galway. She then completed a medical oncology fellowship in the Breast and Ovarian Cancer Program at The Sidney Kimmel Comprehensive Center at Johns Hopkins, during which time she studied under the mentorship of Vered Stearns, MD and Stéphanie Gaillard, MD, PhD.

Dr. Walsh specializes in the treatment of people with breast cancer. As part of a multidisciplinary team, she works closely with other medical oncologists, surgeons, radiation oncologists, nurses, and patient advocates to provide a personalized approach to treatment for her patients.

Dr. Walsh's current research efforts focus on the development of early-phase clinical trials to study breast cancers harboring DNA damage-repair defects and to develop novel targeted therapies to be used in conjunction with, or as an alternative to, chemotherapy. Her work also seeks to advance the understanding of the mechanisms of resistance to therapies with the overarching goal to develop more personalized therapies to treat breast cancer.

In additional to her clinical work, Dr. Walsh also has been involved in medical missions in Uganda, Kenya, and the Philippines. She donates her time, expertise, and fundraising efforts to local hospitals and clinics.